Evaluating the Cost-effectiveness of Realistic Screening Interventions Across Sev

评估跨部门的现实筛查干预措施的成本效益

基本信息

  • 批准号:
    7658018
  • 负责人:
  • 金额:
    $ 25.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-05-01 至 2011-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Evaluating the cost-effectiveness of ophthalmologic screening initiatives can guide decisions about when and where to implement screening. If done well, these analyses can help target scarce visual health resources in a way that maximizes societal well-being at a reasonable cost. The need for targeted visual health screening in the United States is increasing as the U.S. population ages because the epidemiology of major adult visual disorders is age-related. However, assessing the cost-effectiveness of visual screening is complicated by subpopulation differences in the routine use of visual screening services. Models that fail to account for this heterogeneity may lead to erroneous conclusions about where and when screening services are justified. In Aim 1 of this project, we will make substantial improvements to an existing visual health simulation model that will enable it to account for heterogeneous patient screening histories based on empirically observed patient data from the Beaver Dam Eye Study and the Los Angeles Latino Eye Study. The model will be unique in at least three important respects: (1) it will be the only cost-effectiveness model that includes the benefits of preventing multiple eye diseases with a single screening intervention; (2) it will be the only visual health screening model that evaluates the cost-effectiveness of a visual health screening intervention implemented in a realistic, mixed-age group population; and (3) it will be the only visual health model that incorporates real patient data at the individual level, which enables the model to simulate the benefit of screening among a mixed group of heterogeneous patients. In Aim 2, we will use the improved model to estimate the cost-effectiveness of visual health screening interventions when considering the benefits of preventing multiple eye diseases and accounting for patient differences in past service use, insurance coverage, and costs to screen. Finally, in Aim 3, we will use the results from our cost-effectiveness analyses to develop a user-friendly software tool that will enable findings to be disseminated to a wide range of decision makers, practitioners, and researchers in a way that is most meaningful in their individual setting. If successful, the project as a whole could lead to improvements in the targeting of visual health screening services and enhancements to the public welfare at a reasonable cost.
描述(由申请人提供):评估眼科筛查计划的成本效益可以指导何时何地实施筛查的决定。如果做得好,这些分析可以帮助瞄准稀缺的视觉卫生资源,以合理的成本最大化社会福祉。随着美国人口老龄化,美国对有针对性的视力健康筛查的需求正在增加,因为主要成人视力障碍的流行病学与年龄有关。然而,由于常规使用视力筛查服务的人群差异,评估视力筛查的成本效益是复杂的。未能解释这种异质性的模型可能会导致错误的结论,即筛查服务在何时何地是合理的。在该项目的目标1中,我们将对现有的视觉健康模拟模型进行实质性改进,使其能够基于来自Beaver Dam Eye研究和洛杉矶拉丁人眼科研究的经验观察患者数据来考虑不同的患者筛查历史。该模型至少在三个重要方面将是独一无二的:(1)它将是唯一包括通过单一筛查干预措施预防多种眼病的好处的成本效益模型;(2)它将是唯一评估在现实的混合年龄段人群中实施的视觉健康筛查干预措施的成本效益的视觉健康筛查模型;(3)它将是唯一在个人层面纳入真实患者数据的视觉健康模型,这使得该模型能够模拟在混合的不同患者群体中进行筛查的好处。在目标2中,我们将使用改进的模型来评估视力健康筛查干预措施的成本效益,同时考虑到预防多种眼病的好处,并考虑到患者在过去的服务使用、保险覆盖范围和筛查成本方面的差异。最后,在目标3中,我们将利用成本效益分析的结果来开发一个用户友好的软件工具,使研究结果能够以对他们的个人环境最有意义的方式传播给广泛的决策者、从业者和研究人员。如果成功,整个项目可能会以合理的成本改善视觉健康筛查服务的针对性,并加强公共福利。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David B Rein其他文献

Place-Based Measures of Inequity and Vision Difficulty and Blindness.
基于地点的不平等以及视力困难和失明的衡量标准。
  • DOI:
    10.1001/jamaophthalmol.2024.1207
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    8.1
  • 作者:
    Patrice M. Hicks;George Lin;P. Newman;Leslie Niziol;Ming;Maria A. Woodward;A. Elam;D. Musch;Roshanak Mehdipanah;Joshua R Ehrlich;David B Rein
  • 通讯作者:
    David B Rein
Prevalence of Diabetic Retinopathy in Health Care Settings-An Early Warning Sign?
医疗机构中糖尿病视网膜病变的患病率——早期预警信号?
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    8.1
  • 作者:
    David B Rein;J. Wittenborn
  • 通讯作者:
    J. Wittenborn

David B Rein的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David B Rein', 18)}}的其他基金

Developing and Evaluating a Surveillance System for Alzheimer's Dementia In the United States
在美国开发和评估阿尔茨海默氏痴呆症监测系统
  • 批准号:
    10369902
  • 财政年份:
    2022
  • 资助金额:
    $ 25.25万
  • 项目类别:
Developing and Evaluating a Surveillance System for Alzheimer's Dementia In the United States
在美国开发和评估阿尔茨海默氏痴呆症监测系统
  • 批准号:
    10579989
  • 财政年份:
    2022
  • 资助金额:
    $ 25.25万
  • 项目类别:
Research to Enhance the US Vision and Eye Health Surveillance System
加强美国视力和眼健康监测系统的研究
  • 批准号:
    10328471
  • 财政年份:
    2019
  • 资助金额:
    $ 25.25万
  • 项目类别:
Establish a Vision and Eye Health Surveillance System for the Nation
建立国家视力和眼睛健康监测系统
  • 批准号:
    9320018
  • 财政年份:
    2016
  • 资助金额:
    $ 25.25万
  • 项目类别:
Evaluating the Cost-effectiveness of Realistic Screening Interventions Across Sev
评估跨部门的现实筛查干预措施的成本效益
  • 批准号:
    8434966
  • 财政年份:
    2009
  • 资助金额:
    $ 25.25万
  • 项目类别:
Evaluating the Cost-effectiveness of Realistic Screening Interventions Across Sev
评估跨部门的现实筛查干预措施的成本效益
  • 批准号:
    7810575
  • 财政年份:
    2009
  • 资助金额:
    $ 25.25万
  • 项目类别:
Modeling Health Utilization of Medicaid Children
医疗补助儿童的健康利用建模
  • 批准号:
    6554906
  • 财政年份:
    2002
  • 资助金额:
    $ 25.25万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.25万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了